BioSpace News Archive

Assertio Therapeutics, Inc. announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019, after the close of markets.

The U.S. Department of Justice (DOJ) is reviewing a government patent for HIV, according to a retired Centers for Disease Control and Prevention (CDC) scientist.

Researchers with the University of California San Francisco (UCSF) developed a “neural decoder” that translates brain activity to synthesize audible speech. They published their research in the journal Nature.

Eli Lilly and Company announced that as it withdraws Lartruvo (olaratumab) from the market for treatment of advanced soft tissue sarcoma (STS), it is establishing an Access Program for patients currently receiving the drug who may wish to continue.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.

Illumina, Inc. announced its financial results for the first quarter of fiscal year 2019.

The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on April 25, 2019.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its first quarter 2019 financial results after market close on Thursday, May 9, 2019.

Total revenues were $5.7 billion during the first quarter of 2019, compared with $5.5 billion in the first quarter of 2018. Net earnings were $928 million, or $1.23 per diluted share, compared with $717 million, or $.91 per diluted share a year ago.